Skip to main content
SpringerLink
Log in
Book cover

Epigenetics and Disease

Pharmaceutical Opportunities

  • Book
  • © 2011

Overview

Editors:
  1. Susan M. Gasser

    1. for Biomedical Research, Part of the Novartis Research Foundation, Friedrich Miescher Institute, Basel, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. En Li

    1. BioMedical Research Co., Ltd., China Novartis Institutes for, Shanghai, China, People's Republic

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Discusses new approaches to pharmaceutical intervention
  • Includes new findings from stem cell research
  • With numerous illustrations
  • Includes supplementary material: sn.pub/extras

Part of the book series: Progress in Drug Research (PDR, volume 67)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (13 chapters)

  1. Front Matter

    Pages i-x
    Download chapter PDF

  2. DNA Methylation and Cancer

    • Phillippa C. Taberlay, Peter A. Jones
    Pages 1-23

  3. Genome-Wide Epigenetic Modifications in Cancer

    • Yoon Jung Park, Rainer Claus, Dieter Weichenhan, Christoph Plass
    Pages 25-49

  4. DNA Repair and the Control of DNA Methylation

    • Primo Schär, Olivier Fritsch
    Pages 51-68

  5. Errors in Erasure: Links Between Histone Lysine Methylation Removal and Disease

    • Elizabeth M. Duncan, C. David Allis
    Pages 69-90

  6. Histone Modifications in Cancer Biology and Prognosis

    • Siavash K. Kurdistani
    Pages 91-106

  7. Dynamics of Histone Lysine Methylation: Structures of Methyl Writers and Erasers

    • Anup K. Upadhyay, Xiaodong Cheng
    Pages 107-124

  8. Epigenetic Mechanisms of Mental Retardation

    • Anne Schaefer, Alexander Tarakhovsky, Paul Greengard
    Pages 125-146

  9. Histone and DNA Modifications in Mental Retardation

    • Shigeki Iwase, Yang Shi
    Pages 147-173

  10. HDAC Inhibitors and Cancer Therapy

    • Peter W. Atadja
    Pages 175-195

  11. Epigenetic Mechanisms in Acute Myeloid Leukemia

    • Antoine H. F. M. Peters, Juerg Schwaller
    Pages 197-219

  12. The Liver-Specific MicroRNA miR-122: Biology and Therapeutic Potential

    • Witold Filipowicz, Helge Großhans
    Pages 221-238

  13. Transcriptional Regulatory Networks in Embryonic Stem Cells

    • Yun Shen Chan, Lin Yang, Huck-Hui Ng
    Pages 239-252

  14. Small Molecules in Cellular Reprogramming and Differentiation

    • Xu Yuan, Wenlin Li, Sheng Ding
    Pages 253-266

  15. Back Matter

    Pages 267-270
    Download chapter PDF
Back to top

Keywords

About this book

Epigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders. Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML. This volume explores the scientific background for clinical applications of epigenetically active drugs. Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications.

Editors and Affiliations

  • for Biomedical Research, Part of the Novartis Research Foundation, Friedrich Miescher Institute, Basel, Switzerland

    Susan M. Gasser

  • BioMedical Research Co., Ltd., China Novartis Institutes for, Shanghai, China, People's Republic

    En Li

Bibliographic Information

  • Book Title: Epigenetics and Disease

  • Book Subtitle: Pharmaceutical Opportunities

  • Editors: Susan M. Gasser, En Li

  • Series Title: Progress in Drug Research

  • DOI: https://doi.org/10.1007/978-3-7643-8989-5

  • Publisher: Springer Basel

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer Basel AG 2011

  • Hardcover ISBN: 978-3-7643-8988-8Published: 02 October 2010

  • Softcover ISBN: 978-3-0348-0305-2Published: 01 March 2012

  • eBook ISBN: 978-3-7643-8989-5Published: 17 October 2010

  • Series ISSN: 0071-786X

  • Series E-ISSN: 2297-4555

  • Edition Number: 1

  • Number of Pages: X, 270

  • Topics: Gene Function

Publish with us

Policies and ethics

Back to top

Search

Navigation